AHA 2021 | CRAVE: Coffee Safety in Rhythm Disorders

On the one side, caffeine can increase arrythmias or interfere with sleeping, but on the other hand, it helps people feel more energetic and do more physical activity. 

AHA 2021 | CRAVE: Seguridad del café para los trastornos del ritmo

These data contribute to the evidence supporting the fact that people who present, or are at risk of presenting supra ventricular arrythmias or atrial fibrillation might not need to avoid coffee. 

The CRAVE study included 100 young volunteers with no prior arrythmia or heart disease who were instructed to modify caffeine intake habits in two-day blocks. 

Coffee intake did not increase atrial arrythmia, but slightly increased premature ventricular contractions. On the other hand, the day people were allowed to have coffee, they walked 1,000 more steps vs the day coffee was not allowed (p=0.001).

Coffee intake was defined as one standard cup of coffee or an expresso. 

There were no differences between having or not having coffee and the incidence of atrial arrythmia. Also, coffee consumption was associated to fewer supra ventricular tachycardia, but more premature ventricular contractions. 


Read also: AHA 2021 | PALACS: Posterior Left Pericardiotomy Improves Post-Procedural AF.


The day participants were allowed to have coffee, they slept mean 36 minutes less than abstinence day. 

Original Title: The coffee and real-time atrial and ventricular ectopy (CRAVE) trial.

Reference: presentado por Marcus GM durante las sesiones científicas del congreso de la AHA 2021.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACURATE Neo2 Underexpansion: Prevalence and Clinical Implications

While transcatheter aortic valve replacement (TAVR) provides durable clinical benefits across a wide range of patients, technical challenges remain that may affect long-term outcomes....

Spontaneous Left Main Dissection: Clinical Characteristics, management and Outcomes

Courtesy of Dr. Juan Manuel Pérez. Spontaneous left main dissection in an uncommon, and potentially life-threatening, cause of acute MI. The aim of this study,...

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...